| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -58,820 | -72,550 | -58,700 | -53,720 | -108,730 |
| Net Income Growth | +18.92% | -23.59% | -9.27% | +50.59% | -105.03% |
Neumora Therapeutics Inc (NMRA)
1.1700 x 1 1.2100 x 10
Post-market by (Cboe BZX)
1.2000 +0.0700 (+6.19%) 03/24/25 [NASDAQ]
1.1700 x 1 1.2100 x 10
Post-market 1.2100 +0.0100 (+0.83%) 19:20 ET
for Mon, Mar 24th, 2025
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass.
Fiscal Year End Date: 12/31